In contrast, HER2 status was associated or tended to be associated with postmenopausal status (23 vs. 15 % in the reference, p = 0.07), larger tumor size (1.3 cm or larger) (21 vs. 12 % in the reference, p = 0.08), comedo subtype tumors (55 vs. 10 % in the reference, p < 0.0001), presence of necrosis (50 vs. 9 % in the reference, p < 0.0001), and higher NG (NG2 or NG3) (38 vs. 6 % in the reference, p < 0.0001) (Table 2). Here, ERBB2 is linked to neoplasm.